Regenxbio gene therapy approval delayed by FDA MRI findings

Regenxbio's gene therapy refiling plan for spinal conditions blocked by FDA after spine MRI findings

Regenxbio's attempt to refile gene therapy for spinal conditions was halted by the FDA following spine MRI findings. This delay blocks potential treatment pathways for patients with spinal disorders.

In the health sector, this represents a friction point where regulatory review slows access to advanced therapies. For patients needing spinal interventions, it means longer waits for potentially curative options that could alleviate chronic pain or mobility issues.

The source material provides only this level of detail; full context remains with the original reporting.

Source: Fierce Biotech